Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/42412
Type
ArticleCopyright
Restricted access
Embargo date
2051-01-01
Collections
- INI - Artigos de Periódicos [3460]
Metadata
Show full item record
BRIEF REPORT: SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ANTIRETROVIRAL THERAPY
Author
Affilliation
National Institutes of Health. Division of AIDS NIAID. Bethesda, MD, USA.
Harvard T.H. Chan School of Public Health. Boston, MA, USA.
Harvard T.H. Chan School of Public Health. Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of Pennsylvania Perelman. School of Medicine. Philadelphia, PA, USA.
Case Western Reserve University. School of Medicine. Cleveland, OH, USA.
Enhancing Care Foundation. Durban International CRS. Durban, South Africa.
Lancet Laboratories and BARC SA. Johannesburg, South Africa.
KEMRI Centre for Global Health Research. Kisumu, Kenya.
UNC Project. Lilongwe, Malawi.
Voluntary Health Services. CART Clinical Research Site. Chennai, India.
Stellenbosch University. FAM-CRU CRS. Cape Town, South Africa.
Social & Scientific Systems. Silver Spring, MD, USA.
University of Nebraska Medical Center. Omaha, NE, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of Washington. School of Medicine. Seattle, WA, USA.
Harvard T.H. Chan School of Public Health. Boston, MA, USA.
Harvard T.H. Chan School of Public Health. Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of Pennsylvania Perelman. School of Medicine. Philadelphia, PA, USA.
Case Western Reserve University. School of Medicine. Cleveland, OH, USA.
Enhancing Care Foundation. Durban International CRS. Durban, South Africa.
Lancet Laboratories and BARC SA. Johannesburg, South Africa.
KEMRI Centre for Global Health Research. Kisumu, Kenya.
UNC Project. Lilongwe, Malawi.
Voluntary Health Services. CART Clinical Research Site. Chennai, India.
Stellenbosch University. FAM-CRU CRS. Cape Town, South Africa.
Social & Scientific Systems. Silver Spring, MD, USA.
University of Nebraska Medical Center. Omaha, NE, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of Washington. School of Medicine. Seattle, WA, USA.
Abstract
Background: Sex differences in studies of antiretroviral (ART) drug exposure and treatment outcomes support the hypothesis that some ART combinations may not be well tolerated in women. We evaluated disparities in outcomes between men and women participating in ACTG A5288, an interventional strategy trial for individuals failing a protease inhibitor-based second-line ART regimen in low- and middle-income countries.
Methods: Participants were assigned to one of 4 cohorts (A-D) based on resistance profiles and ART history. Cohort A had no lopinavir/ritonavir (LPV/r) resistance and stayed on their second-line regimen, and cohorts B, C, and D had increasing resistance and accessed novel ART regimens. In this secondary analysis, we evaluated sex differences in the primary endpoint, HIV-1 RNA ≤200 copies/mL at week 48; confirmed virologic failure ≥1000 copies/mL (VF); and clinical outcomes and adverse events (intent-to-treat).
Results: Women made up 258/545 (47%) of the study population. More women than men were assigned to cohort A. Median follow-up was 72 weeks. Fewer women than men had HIV-1 RNA ≤200 copies/mL at week 48: 39% vs. 49% in cohort A and 83% vs. 89% in cohorts B, C, and D combined. More women experienced VF, grade ≥3 signs and symptoms, but similar grade ≥3 diagnoses or laboratory abnormalities.
Conclusions: More women than men entered the study with a resistance profile suggesting that their second-line regimen could have been effective in maintaining virologic suppression. The more frequent occurrence of grade ≥3 signs and symptoms in women suggests that tolerability issues were under recognized in women on protease inhibitor-based therapy.
Share